ROIVANT SCIENCES LTD(NASDAQ:ROIV) stock News

ROIV Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Yahoo Finance

Why Roivant Sciences Stock Bounced Back on Tuesday

16 days ago - By: The Motley Fool

Why Roivant Sciences Stock Bounced Back on Tuesday

18 days ago - By: Yahoo Finance

Why Roivant Sciences Stock Was Slipping on Monday

18 days ago - By: The Motley Fool

Why Roivant Sciences Stock Was Slipping on Monday

18 days ago - By: Yahoo Finance - Mentions: ABX UBS TSLA EA ...

Stock Market Today: S&P 500 upgraded by Citi, UBS

21 days ago - By: Benzinga

A Glimpse of Roivant Sciences's Earnings Potential

a month ago - By: Benzinga

What Does the Market Think About Roivant Sciences?

18 days ago - By: Zacks Investment Research - Mentions: FENC

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

18 days ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

18 days ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

22 days ago - By: Zacks Investment Research - Mentions: KURA

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

24 days ago - By: Zacks Investment Research - Mentions: RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

a month ago - By: Roivant Sciences

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

a month ago - By: Roivant Sciences

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

2 months ago - By: Pulmovant, Inc.

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

3 months ago - By: Roivant Sciences

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

3 months ago - By: Roivant Sciences

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

3 months ago - By: Zacks Investment Research - Mentions: XAIR

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

3 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

3 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

3 months ago - By: Yahoo Finance - Mentions: UBS WLK IMVT TRML ...

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

3 months ago - By: Yahoo Finance - Mentions: UBS WLK IMVT DHI ...

UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating

3 months ago - By: Yahoo Finance - Mentions: TRML IMVT DHI CMG

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

4 months ago - By: Zacks Investment Research - Mentions: GOSS

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Roivant Sciences

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

4 months ago - By: Roivant Sciences

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

4 months ago - By: Zacks Investment Research - Mentions: CDXS

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: LQDA

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: IVZ CRS GMED

Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?

4 months ago - By: Yahoo Finance - Mentions: GLRE MSFT DHI CMG

ROIVANT SCIENCES LTD (ROIV) Stock News

ROIV Latest News, Press Relases and Analysis

Why Roivant Sciences Stock Bounced Back on Tuesday

Why Roivant Sciences Stock Bounced Back on Tuesday

Why Roivant Sciences Stock Was Slipping on Monday

Why Roivant Sciences Stock Was Slipping on Monday

Stock Market Today: S&P 500 upgraded by Citi, UBS

A Glimpse of Roivant Sciences's Earnings Potential

What Does the Market Think About Roivant Sciences?

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates

Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?

Roivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside Potential